Navigation Links
Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
Date:10/24/2007

Napa, CA (October 24, 2007) Data presented today at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), demonstrate concomitant use of nebulized formoterol fumarate and tiotropium provided improved bronchodilation over tiotropium monotherapy and was well-tolerated in this clinical study. The only commercially available version of nebulized formoterol fumarate is Perforomist Inhalation Solution, which is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Formoterol fumarate is a rapid and long-acting beta2-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation and has twenty years of worldwide experience. Perforomist Inhalation Solution is the first and only FDA-approved nebulized form of this molecule. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

Results presented were from Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol and Tiotropium in COPD, a randomized, placebo-controlled Phase IIIb trial. The trial demonstrated that concomitant therapy with twice-daily nebulized formoterol fumarate (FFIS) and once-daily tiotropium provided patients with statistically significant and clinically relevant improvements in bronchodilation over treatment with tiotropium alone. In this six-week study, patients receiving concomitant therapy with nebulized FFIS and tiotropium experienced fewer adverse events or COPD exacerbations than patients receiving placebo or tiotropium monotherapy.

According to Donald P. Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles and the lead clinical investigator, For the patients in this study, adjunctive use of nebulized formoterol fumarate and tiotropium showed statistically significant improvements in lung function by improving bronchodilation over use of tiotropium alone. For physicians, Perforomist Inhalation Solution and commonly prescribed long-acting anticholinergics such as tiotropium offers a new and valuable treatment option for COPD patients with moderate to severe manifestations of the disease.

Christy Taylor, Chief Operating Officer at Dey, L.P., commented, At DEY, we specialize in developing effective new treatments for serious and complex respiratory diseases, and it is gratifying that the newest addition to our franchise, Perforomist Inhalation Solution, offers physicians additional prescribing flexibility. For over a decade, Dey, L.P. has been the U.S. leader in sales of nebulized respiratory medication. We thank Dr. Tashkin and the other members of the research team for their assessment of how Perforomist Inhalation Solution may be used concomitantly with tiotropium for improved clinical effect for COPD patients.

For those attending CHEST 2007, the presentation is available as follows:

Poster viewing: Session ID 902 - COPD Treatment II
Wednesday, October 24, 2007, 12:30 2:00 PM
Convention Center, Exhibit Hall, McCormick Place, Lakeside Center, Chicago.

Poster # 251: Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol and Tiotropium in COPD


'/>"/>

Contact: Amy Techtmann
amy.techtmann@fkhealth.com
617-761-6784
Feinstein Kean Healthcare
Source:Eurekalert

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: